Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Claire Leurent is active.

Publication


Featured researches published by Claire Leurent.


Alzheimers & Dementia | 2012

Systems pharmacology modeling in 5HT4: Prediction and outcome of a clinical scopolamine impairment trial and further application to Alzheimer's disease pathology

Timothy Nicholas; Sridhar Duvvuri; Claire Leurent; David Raunig; Tracey L. Rapp; Phillip Iredale; Carolyn Rowinski; Robert Carr; Patrick Roberts; Athan Spiros; Hugo Geerts

then challenged orally with CWD infected brains. Tonsil and rectal biopsies plus blood, saliva, feces and urine were collected every three months post-infection until the 9 month; and every 45 days thereafter. Results: Two vaccinated animals produced low antibody titers, two intermediate titers and one high titers of IgA and IgG anti-PrP. Both groups produced high titers of IgA and IgG against Salmonella. Six months post-infection 5 out of 6 controls and 3 out of 5 vaccinated showed histologically prion structures in the tonsils. Ayear post-infection one of the vaccinated animals remained prion free, with all controls being infected. The negative animal has the highest titers of IgA in saliva and IgG systemic against PrP. Immunoglobulins purified from saliva, feces and serum of this vaccinated deer reacts to PrP. Conclusions: Oral immunization can be used to overcome tolerance to self-PrP protein and produce a mucosal IgA and systemic IgG response to normal and conformational modified PrP in large mammals. High antibody titers might be enough to prevent transmission or to retard progression of PrP infection. This approach may lead to an effective anti-prion vaccine.


Alzheimers & Dementia | 2016

LOW PREVALENCE OF AMYLOID POSITIVITY IN HEALTHY ELDERLY PARTICIPANTS OF A METHODOLOGY STUDY EVALUATING REMOTE TABLET-BASED COGNITIVE LEARNING

Claire Leurent; James Goodman; Eve H. Pickering; Ping He; Sridhar Duvvuri; Eddie Martucci; Scott Kellogg; Derek Purcell; Jerome Barakos; Gregory Klein; James W. Kupiec; Robert C. Alexander

Conclusions Though a gold standard of amyloid burden was not available, results indicate that a hybrid qualitative visual / quantitative method can be used to obtain greater concordance between quantitative and visual results. Clinical studies using only visual or only SUVR information for eligibility decisions must understand the implications of potential differences between the visual and quantitative methodologies.


Advances in Alzheimer's Disease | 2013

Systems pharmacology modeling in neuroscience: Prediction and outcome of PF-04995274, a 5-HT4 partial agonist, in a clinical scopolamine impairment trial

Timothy Nicholas; Sridhar Duvvuri; Claire Leurent; David Raunig; Tracey L. Rapp; Phil Iredale; Carolyn Rowinski; Robert Carr; Patrick Roberts; Athan Spiros; Hugo Geerts


Alzheimers & Dementia | 2012

A randomized, double-blind, sponsor-unblinded, placebo- and positive-controlled study to evaluate the effects of single oral administrations of PF-04995274 on scopolamine-induced deficits in cognitive function in healthy adults

Claire Leurent; Sridhar Duvvuri; David Raunig; Jeremias Antinew; Carolyn Rowinski; Laura Zumpano; Michelle Bergeron; Hetal S. Kocinsky; Joy Sieklucki; Timothy Nicolas; Tracey L. Rapp


Alzheimers & Dementia | 2011

Translational receptor occupancy for the 5-HT4 partial agonist PF-04995274 in rats, non-human primates and healthy volunteers

Sarah Grimwood; Elena M. Drummond; Ken Zasadny; Marc B. Skaddan; Michael Aaron Brodney; Karen Coffman; Timothy Nicholas; Sridhar Duvvuri; David Raunig; Claire Leurent; Carolyn Rowinski; Yo-sub Park; Adam Ogden; Aarti Sawant; Emily Miller; Tracey L. Rapp; Yi Wang; Beata Planeta-Wilson; Jim Ropchan; Richard E. Carson; Evan D. Morris; Yu-Shin Ding; Elyse Katz


Alzheimers & Dementia | 2012

Modulation of soluble APPα in brain by PF-04995274, a 5HT4 partial agonist, following single oral doses in healthy human volunteers: Study design and PK-PD analysis

Sridhar Duvvuri; Timothy Nicholas; Claire Leurent; David Raunig; Anna Plotka; Elias Schwam; Sarah Grimwood; Carolyn Rowinski; Tracey L. Rapp


Alzheimers & Dementia | 2016

PF-06648671–A NOVEL GAMMA SECRETASE MODULATOR: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON PLASMA AMYLOID-B LEVELS FOLLOWING SINGLE ORAL ASCENDING DOSES IN HEALTHY VOLUNTEERS

Ruolun Qiu; Richann Liu; Anne Marie Wills; Ping He; Claire Leurent; Eva Hajos-Korcsok; Laure Mendes da Costa; Robert C. Alexander


Alzheimers & Dementia | 2012

A comparison of crossover versus parallel-arm clinical study designs in evaluating the psychomotor and cognitive deficits induced by scopolamine

Claire Leurent; Joanne Bell; Sridhar Duvvuri; David Raunig; Hifan Huang; Anna Plotka; James P. Mancuso; Tracey L. Rapp; Grace M. Vandal; Clare B. Billing; James W. Kupiec


Alzheimers & Dementia | 2011

ORL1: A Novel Mechanism With Potential to Provide Beneficial Effects for Depressive Symptoms Associated With Alzheimer's Disease (AD)

Rathna Iyer; Allen J. Duplantier; Michael Aaron Brodney; Bradley Snyder; Elizabeth C. Arnold; Laura McDowell; Claire Leurent; Faith Prior; Panayiotis Zagouras; Robin Roof


Alzheimers & Dementia | 2011

Pharmacokinetics, safety and tolerability of PF-04995274: A 5HT4 partial agonist being developed for the treatment of Alzheimer's disease

Timothy Nicholas; David Raunig; Sridhar Duvvuri; Anna Plotka; Elias Schwam; Sarah Grimwood; Yo-sub Park; Carolyn Rowinski; Tracey L. Rapp; Michelle Bergeron; Claire Leurent

Collaboration


Dive into the Claire Leurent's collaboration.

Researchain Logo
Decentralizing Knowledge